Loading clinical trials...

Autologous Platelet Lysate in Corneal Epithelial Defects | Clinical Trials | Clareo Health

COMPLETEDPHASE1/PHASE2

Autologous Platelet Lysate in Corneal Epithelial Defects

The Use of Autologous Platelet Lysate in Persistent Corneal Epithelial Defects

NCT02979912•Hanan Jafar

View on ClinicalTrials.gov

Summary

Patients diagnosed with persistent corneal epithelial ulcers will be treated with autologous platelet lysate.

Detailed Description

Autologous platelet lysate (PL) will be given to patients diagnosed with persistent corneal epithelial ulcers (PED) who are unresponsive to conventional therapy to promote the healing of PED. PL will be dispensed into sterile eye droppers, and these eye droppers will be stored ideally at -20C and thaw once for use, then will be kept in the refrigerator at +4C, to be taken in multiple doses.

Eligibility

Age

21 - 78 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Cognitive ability to understand and sign the consent form.
•2. Corneal ulcers that did not re-epithelialise after 1 week of conventional treatment (therapeutic contact lenses, topical artificial tears, eye packs and antibiotic eye-drops).
•3. Clinical indications: corneal ulcer due to caustic substances, corneal epitheliopathy, corneal lesions following cataract surgery, recurrent ulcerative keratitis, corneal lesions due to a foreign body.
•4. Good compliance with the study regimen and availability for the duration of the entire study period.

Exclusion Criteria

•1. Corneal ulcers which developed tissue scars.
•2. Pregnant or lactating women.

Locations (1)

Cell Therapy Center

Amman, Jordan

Key Dates

Start Date

February 16, 2017

Primary Completion Date

January 15, 2019

Completion Date

January 30, 2019

Last Updated

March 3, 2021

Enrollment

ACTUAL participants

Conditions

Persistent Corneal Epithelial Defect

Interventions

Platelet Lysate

BIOLOGICAL

Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease

NCT06919081

Persistent Corneal Epithelial DefectCorneal Epithelial Disorders

View study

RECRUITINGPHASE2

A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED

NCT05966493

Persistent Corneal Epithelial Defect

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 3, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Autologous Platelet Lysate in Corneal Epithelial Defects

Inclusion Criteria

Exclusion Criteria

Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease

A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED

A Study of the KIO-201 (Ocular Bandage Gel) for Improving Persistent Corneal Epithelial Defects

Platelet Rich Plasma in Corneal Surface Diseases

Use of a Biological Lens of Amniotic Membrane (LV-Visio-AMTRIX) in the Treatment of Trophic Ulcers